Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12

Cancer Research

Volumn 59, Issue 19, 1999, Pages 4882-4889

  Gee, Michael S ^a   Koch, Cameron J ^a   Evans, Sydney M ^a   Jenkins, W Timothy ^a   Pletcher Jr , Charles H ^a   Moore, Jonni S ^a   Koblish, Holly K ^a   Lee, Jungeun ^b   Lord, Edith M ^b   Trinchieri, Giorgio ^c   Lee, M F William ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 12;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CONTROL; CELL HYPOXIA; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; FEMALE; FLOW CYTOMETRY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

ANIMALS; APOPTOSIS; CELL HYPOXIA; COLLAGEN; DRUG COMBINATIONS; FEMALE; INTERFERON-GAMMA, RECOMBINANT; INTERLEUKIN-12; ISCHEMIA; LAMININ; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C3H; NEOVASCULARIZATION, PATHOLOGIC; PROTEOGLYCANS; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 0033214696     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., and Gately, M. K. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med., 178: 1223-1230, 1993.
2. Zitvogel, L., Tahara, H., Robbins, P. D., Storkus, W. J., Clarke, M. R., Nalesnik, M. A., and Lotze, M. T. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J. Immunol., 155: 1393-1403, 1995.
3. Tahara, H., Zitvogel, L., Storkus, W. J., Zeh, H. J., McKinney, T. G., Schreiber, R. D., Gubler, U., Robbins, P. D., and Lotze, M. T. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol., 154: 6466-6474, 1995.
4. Coughlin, C. M., Wysocka, M., Trinchieri, G., and Lee, W. M. F. The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12. Cancer Res., 57: 2460-2467, 1997.
5. Coughlin, C. M., Wysocka, M., Hurzawa, H. L., Lee, W. M. F., Trinchieri, G., and Eck, S. L. B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res., 55: 4980-4987, 1995.
6. Brunda, M. J. Role of IL-12 as an anti-tumor agent: current status and future directions. Res. Immunol., 146: 622-628, 1995.
7. Trinchieri, G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol., 13: 251-276, 1995.
8. Kurzawa, H., Wysocka, M., Aruga, E., Chang, A. E., Trinchieri, G., and Lee, W. M. F. Interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression. Cancer Res., 58: 491-499, 1998.
9. Koblish, H. K., Hunter, C. A., Wysocka, M., Trinchieri, G., and Lee, W. M. F. Immune suppression by recombinant interleukin (rIL)-12 involves interferon γ induction of nitric oxide synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of rlL-12 vaccine adjuvant effect. J. Exp. Med., 188: 1603-1610, 1998.
10. Voest, E. E., Kenyon, B. M., O'Reilly, M. S., Truitt, G., D'Amato, R. J., and Folkman, J. Inhibition of angiogenesis in vivo by interleukin-12. J. Natl. Cancer Inst., 87: 581-586, 1995.
11. Sgadari, C., Angiolillo, A. L., and Tosato, G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein-10. Blood, 87: 3877-3882, 1996.
12. Coughlin, C. M., Salhany, K. E., Gee, M. S., LaTemple, D. C., Kotenko, S., Ma, X. J., Gri, G., Wysocka, M., Kim, J. E., Liu, L., Liao, F., Farber, J. M., Pestka, S., Tranchiert, G., and Lee, W. M. F. Tumor cell responses to IFN-γ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity, 9: 25-34, 1998.
13. Majewski, S., Marczak, M., Szmurlo, A., Jablonska, S., and Bollag, W. Interleukin-12 inhibits angiogenesis induced by human tumor cell lines in vivo. J. Invest. Dermatol., 106: 1114-1118, 1996.
14. Dias, S., Boyd, R., and Balkwill, F. IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int. J. Cancer, 78: 361-365, 1998.
15. Ruegg, C., Yilmaz, A., Bieler, G., Bamat, J., Chaubert, P., and Lejeune, F. J. Evidence for the involvement of endothelial cell integrin αVβ3 in the disruption of the tumor vasculature induced by TNF and IFN-γ. Nat. Med., 4: 408-414, 1998.
16. O'Reilly, M. S., Holmgren, L., Chen, C., and Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med., 2: 689-692, 1996.
17. Holmgren, L., O'Reilly, M. S., and Folkman, J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis inhibition. Nat. Med., 1: 149-153, 1995.
18. An, W. G., Kanekal, M., Simon, M. C., Maltepe, E., Blagosklonny, M. V., and Neckers, L. M. Stabilization of wild-type p53 by hypoxia-inducible factor 1a. Nature (Lond.), 392: 405-408, 1998.
19. Carmeliet, P., Dor, Y., Herbert, J. M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovich, R., Maxwell, P., Koch, C. J., Ratcliffe, P., Moons, L., Jain, R. K., Collen, D., and Keshet, E. Role of HIF-1a in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature (Lond.), 394: 485-490, 1998.
20. Kripke, M. Speculations on the role of ultraviolet radiation in the development of malignant melanoma. J. Natl. Cancer Inst., 63: 541-545, 1979.
21. Evans, S. M., Jenkins, W. T., Joiner, B., Lord, E. M., and Koch, C. J. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Cancer Res., 56: 405-411, 1996.
22. Lee, J., Fenton, B. M., Koch, C. J., Frelinger, J. G., and Lord, E. M. Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment. Cancer Res., 58: 1478-1485, 1998.
23. Lord, E. M., Harwell, L., and Koch, C. J. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res., 53: 5721-5726, 1993.
24. 2 tension. Am. J. Physiol., 271: C1172-C1180, 1998.
25. Chin, Y. E., Kitagawa, M., Kuida, K., Flavell, R., and Fu, X. Y. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol. Cell. Biol., 17: 5328-5337, 1997.
26. Koch, C. J., Evans, S. M., and Lord, E. M. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-l-y1)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]: analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br. J. Cancer, 72: 869-874, 1995.
27. Evans, S. M., Laughlin, K. M., Pugh, C. R., Sehgal, C. M., and Saunders, H. M. Use of power Doppler ultrasound-guided biopsies to locate regions of tumour hypoxia. Br. J. Cancer, 76: 1308-1314, 1997.
28. Schmaltz, C., Hardenbergh, P. H., Wells, A., and Fisher, D. E. Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol. Cell. Biol., 18: 2845-2854, 1998.
29. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.
30. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (Lond.), 390: 404-407, 1997.
31. Pham-Nguyen, K. B., Yang, W., Saxena, R., Thung, S. N., Woo, S. L., and Chen, S. H. Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma. Int. J. Cancer, 81: 813-819, 1999.
32. Yao, L., Sgadari, C., Furuke, K., Bloom, E. T., Teruya-Feldstein, J., and Tosato, G. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood, 93: 1612-1621, 1999.
33. Guillemin, K., and Krasnow, M. A. The hypoxic response: huffing and HIFing. Cell, 89: 9-12, 1997.
34. Horsman, M. R., and Overgaard, J. The oxygen effect. In: G. G. Steel (ed.), Basic Clinical Radiobiology, pp. 132-140. New York: Oxford University Press, 1997.
35. Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., and Giaccia, A. J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature (Lond.), 379: 88-91, 1996.
36. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
37. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
38. Kerbel, R. S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anticancer therapeutic agents. BioEssays, 13: 31-36, 1991.